BioSpecifics Technologies Corp. Announces Launch of XIAPEX by Pfizer for Treatment of Dupuytren's Contracture in Europe

BioSpecifics Technologies Corp. BSTC today announced that it will receive a $2.5 million milestone payment as a result of the European launch and first commercial sale of XIAPEX in the United Kingdom, a major European market. Pfizer, Inc. PFE, the EU licensee received approval from the European Medicines Agency to market XIAPEX in Europe for the treatment of Dupuytren's contracture, a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers. XIAPEX is the first injectable treatment to be approved in the EU for the treatment of this indication, which affects approximately 13% of the European population.